NASDAQ:ADAP - Adaptimmune Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $10.44 -0.54 (-4.92 %) (As of 07/20/2018 04:00 PM ET)Previous Close$10.44Today's Range$10.36 - $10.954552-Week Range$4.82 - $14.63Volume535,152 shsAverage Volume317,244 shsMarket Capitalization$1.03 billionP/E Ratio-13.05Dividend YieldN/ABeta1.19 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom. Receive ADAP News and Ratings via Email Sign-up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:ADAP CUSIPN/A Webwww.adaptimmune.com Phone44-12-3543-0000 Debt Debt-to-Equity RatioN/A Current Ratio3.77 Quick Ratio3.77 Price-To-Earnings Trailing P/E Ratio-13.05 Forward P/E Ratio-11.86 P/E GrowthN/A Sales & Book Value Annual Sales$37.83 million Price / Sales25.98 Cash FlowN/A Price / CashN/A Book Value$2.17 per share Price / Book4.81 Profitability EPS (Most Recent Fiscal Year)($0.80) Net Income$-70,130,000.00 Net Margins-160.83% Return on Equity-32.57% Return on Assets-24.93% Miscellaneous Employees371 Outstanding Shares94,140,000Market Cap$1,033.69 Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions What is Adaptimmune Therapeutics' stock symbol? Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP." How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) posted its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.20. The biotechnology company earned $8.20 million during the quarter, compared to analyst estimates of $7.59 million. Adaptimmune Therapeutics had a negative net margin of 160.83% and a negative return on equity of 32.57%. During the same period in the prior year, the firm earned ($3.00) earnings per share. View Adaptimmune Therapeutics' Earnings History. When is Adaptimmune Therapeutics' next earnings date? Adaptimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Adaptimmune Therapeutics. What price target have analysts set for ADAP? 4 equities research analysts have issued 1 year price targets for Adaptimmune Therapeutics' shares. Their forecasts range from $18.00 to $20.00. On average, they expect Adaptimmune Therapeutics' stock price to reach $19.3333 in the next twelve months. This suggests a possible upside of 85.2% from the stock's current price. View Analyst Ratings for Adaptimmune Therapeutics. What is the consensus analysts' recommendation for Adaptimmune Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Adaptimmune Therapeutics stock? Here are some recent quotes from research analysts about Adaptimmune Therapeutics stock: 1. According to Zacks Investment Research, "Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. " (7/10/2018) 2. Cowen Inc analysts commented, "We continue to expect positive data for the five-dose combination Phase 2 cohorts in 3Q18, and anticipate sustained serum uric acid suppression without ADAs. Selecta will present data for patients receiving 0.10 – 0.15 mg/kg SVP rapamycin combined with 0.2 mg/kg pegsiticase. The company plans to present multiple cohorts with up to n=20 patients per group. We expect data in 3Q18 to include a number of patients who have completed the full 5/6 dose combination regimen." (5/9/2018) 3. Raymond James analysts commented, "Benjamin observed: Benjamin observed: We are maintaining our Outperform rating and increasing our price target to $20 (previously was $11) for ADAP given our increasing confidence in the company’s TCR franchise. Yesterday, the company reported 4Q17 financial results and provided an update on its TCR programs. Key takeaways include: 1) three partial responses (PRs) achieved by the NY- ESO TCR among four patients with myxoid/ round cell liposarcoma (MRCLS); 2) a slew of additional data readouts expected throughout 2018, including the first efficacy results from the MAGE-A10 and MAGE-A4 studies anticipated in 2H18; and 3) a cash runway through early 2020. With growing evidence from the NY-ESO TCR, multiple clinical data readouts expected from the wholly owned assets in 2018, a marquee partner like GlaxoSmithKline to move the NY-ESO program into pivotal studies, and a strong cash position of $188 million (pro forma), we continue to recommend shares of Adaptimmune to long-term, risk tolerant investors." " (4/22/2018) Who are some of Adaptimmune Therapeutics' key competitors? Some companies that are related to Adaptimmune Therapeutics include Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Repligen (RGEN), Acceleron Pharma (XLRN), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), Solid Biosciences (SLDB) and Sangamo Therapeutics (SGMO). Who are Adaptimmune Therapeutics' key executives? Adaptimmune Therapeutics' management team includes the folowing people: Mr. James Julian Noble, CEO & Director (Age 59)Dr. Bent Jakobsen Ph.D., Scientific Co-FounderDr. Helen Katrina Tayton-Martin, Co-Founder and Chief Bus. Officer (Age 51)Mr. Adrian Rawcliffe, Chief Financial Officer (Age 46)Mr. William C. Bertrand Jr., Chief Operating Officer (Age 53) When did Adaptimmune Therapeutics IPO? (ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager. Has Adaptimmune Therapeutics been receiving favorable news coverage? News coverage about ADAP stock has trended somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adaptimmune Therapeutics earned a coverage optimism score of 0.10 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.03 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. Who are Adaptimmune Therapeutics' major shareholders? Adaptimmune Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.22%), Dorsey Wright & Associates (0.62%), Essex Investment Management Co. LLC (0.18%), Fred Alger Management Inc. (0.03%) and Atria Investments LLC (0.02%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, David M Mott, Enterprise Associates 14 New, Orbimed Advisors Llc, Peter A Thompson and Ravi Viswanathan. View Institutional Ownership Trends for Adaptimmune Therapeutics. Which major investors are selling Adaptimmune Therapeutics stock? ADAP stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Orbimed Advisors Llc and Peter A Thompson. View Insider Buying and Selling for Adaptimmune Therapeutics. Which major investors are buying Adaptimmune Therapeutics stock? ADAP stock was acquired by a variety of institutional investors in the last quarter, including Dorsey Wright & Associates, Baillie Gifford & Co., Fred Alger Management Inc. and Atria Investments LLC. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include David M Mott, Enterprise Associates 14 New, Orbimed Advisors Llc and Ravi Viswanathan. View Insider Buying and Selling for Adaptimmune Therapeutics. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Adaptimmune Therapeutics' stock price today? One share of ADAP stock can currently be purchased for approximately $10.44. How big of a company is Adaptimmune Therapeutics? Adaptimmune Therapeutics has a market capitalization of $1.03 billion and generates $37.83 million in revenue each year. The biotechnology company earns $-70,130,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Adaptimmune Therapeutics employs 371 workers across the globe. How can I contact Adaptimmune Therapeutics? Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected] MarketBeat Community Rating for Adaptimmune Therapeutics (NASDAQ ADAP)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 164 (Vote Outperform)Underperform Votes: 146 (Vote Underperform)Total Votes: 310MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics and other stocks. Vote "Outperform" if you believe ADAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADAP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?